B
Blue Owl Capital
Alternative asset manager that provides investors access to direct lending and GP capital solutions strategies through a variety of vehicles
About Blue Owl Capital
Owl Rock is a leading alternative asset manager with deep expertise in the credit markets. Our strength lies in the experience of our investment team and our ability to view the credit markets through multiple lenses.
Backed by a dedicated team of investment professionals with diverse credit underwriting expertise across a variety of industries, each of our partners offers a unique perspective that, together, provides a holistic view of the investment process and a thorough understanding of the risks and opportunities in today’s credit markets.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2021
- Headquarters
- New York City, United States
- Listing
- Public via SPAC 2020
- Employees
- 1,583
- Open positions
- 60
- Dealroom signal
- 76.5/100
- Industry
- Fintech
- Sector
- Fintech
- Business model
- SaaS
- Client focus
- b2b
- Investment activity
- 136 companies, latest Sep 2026
- Capital deployed
- $13B
- Preferred round
- DEBT
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Sep 2026 | $1B | — | Undisclosed | ↗ |
| POST IPO DEBT✓Debt | Sep 2026 | $150M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Blue Owl Capital is 84K monthly website visits, down 30% over the last three months. Blue Owl Capital's team grew 4.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Hasso Plattner Venture CapitalSeed-stage capital for European B2B tech startups. |
Germany | Operational | 9 | — | — |
 GPGPTAI platform for venture capital and private equity. |
San Francisco, United States | Operational | |||
 Trivera VenturesPre-seed and seed fund for AI, HealthTech, ClimateTech. |
— | Operational | |||
 ġatekeepAI-powered platform for venture capital discovery. |
— | Operational | |||
 Fons.vcStructured startup profiles for evidence-based investing. |
London, United Kingdom | Operational | |||
 Minerva Investments, LLCPurpose-driven capital for growth-stage technology companies. |
— | Operational | |||
 MayrockStrategic capital and execution for GCC technology. |
— | Operational | |||
 Jett VenturesonAI-powered deal flow and networking for investors. |
Menlo Park, United States | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
PowerHouse Data CentersTysons, United States
→
WE
WoodStar Reciprocal ExchangeSandy Springs, United StatesSpecialty commercial insurance for small, medium businesses.
→
Cleveland CavaliersCleveland, United StatesCleveland Cavaliers | Cleveland Cavaliers Team News
→
CAISNew York City, United StatesFinancial technology platform that provides independent wealth channels with access to alternative investments
$2Bvaluation
Corscale Data CentersHouston, United StatesSustainable hyperscale data center development and operation.
→
PerkBarcelona, SpainFormerly TravelPerk. Integrated business‐platform streamlining corporate travel booking, expense processing and spend control
$2.7Bvaluation
Windward BioBasel, SwitzerlandBiopharmaceutical company advancing treatments for oncology, immunology, and rare diseases with a focus on commercialization
$825Mvaluation
Artiva BiotherapeuticsSan Diego, United StatesNK cell therapy for cancer patients
$37Mvaluation
Sila Realty TrustTampa, United StatesSila Realty Trust, Inc. is a non-traded REIT based in Tampa, FL. It invests in premium healthcare properties, capitalizing on economic growth
$2.4Bvaluation
Caris Life SciencesIrving, United StatesA profiling platform that identifies novel molecular targets to inform and enhance drug development and advanced diagnostics
$8.6Bvaluation
Sagimet BiosciencesSan Mateo, United StatesClinical-stage biopharmaceutical developing selective fatty acid synthase (FASN) inhibitors for metabolic, oncology and dermatology indications.
$409Mvaluation
Ambrosia BiosciencesBoulder, United StatesSmall molecule therapies for obesity and metabolic disorders, delivered orally
$400Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Altimar Acquisition Corp
Other known investors1 additional known investor
Alder Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Blue Owl Capital on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Blue Owl Capital’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.